|34.14 0.7 (2.09%)||12-08 16:00|
|Targets||6-month :||45.43||1-year :||50.22|
|Resists||First :||38.9||Second :||43|
|Supports||First :||32.27||Second :||26.84|
|MAs||MA(5) :||34.36||MA(20) :||38.2|
|MA(100) :||43.03||MA(250) :||43.81|
|MACD||MACD :||-1.2||Signal :||-0.5|
|%K %D||K(14,3) :||11.6||D(3) :||16.1|
|52-week||High :||59.61||Low :||32.27|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ATRC ] has closed above bottom band by 23.4%. Bollinger Bands are 71.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 16 days. This is a sign that the current trend might continue.
|If tomorrow:||Open lower||Open higher|
|High:||34.52 - 34.68||34.68 - 34.83|
|Low:||32.55 - 32.74||32.74 - 32.91|
|Close:||33.82 - 34.14||34.14 - 34.43|
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
Tue, 14 Nov 2023
AtriCure Releases 2023 ESG Report - Business Wire
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Medical Instruments & Supplies
|Shares Out||47 (M)|
|Shares Float||46 (M)|
|Held by Insiders||2.4 (%)|
|Held by Institutions||99 (%)|
|Shares Short||1,620 (K)|
|Shares Short P.Month||1,180 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||9.77|
|Profit Margin||-6.6 %|
|Operating Margin||-8.3 %|
|Return on Assets (ttm)||-2.4 %|
|Return on Equity (ttm)||-5.5 %|
|Qtrly Rev. Growth||18.1 %|
|Gross Profit (p.s.)||5.18|
|Sales Per Share||8.03|
|Qtrly Earnings Growth||0 %|
|Operating Cash Flow||1 (M)|
|Levered Free Cash Flow||-8 (M)|
|Price to Book value||3.49|
|Price to Sales||4.25|
|Price to Cash Flow||3236.47|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|